Medical Pharmacology Question Bank: ANS Cholinergic Pharmacology — Module 3 | Tier 1 — Foundational Recall
Chapter 6: Cholinergic Pharmacology — Module 3: Nicotinic Pharmacology — NMJ, Ganglionic, and CNS Drugs
Tier 1 — Foundational Recall
1. Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels whose subunit composition differs substantially across anatomic sites, and this compositional heterogeneity underlies the selectivity of several clinically important drugs. A pharmacology resident is asked to identify the predominant subunit composition of the nicotinic receptor expressed at the adult mammalian neuromuscular junction (NMJ), which is the molecular target of both depolarizing and nondepolarizing neuromuscular blocking agents. Which of the following subunit compositions correctly describes the adult NMJ nicotinic receptor?
ANSWER: C
Rationale:
The adult NMJ nicotinic receptor has the composition (α1)₂β1δε. During fetal development and in the early postnatal period, the endplate receptor contains a γ subunit instead of ε [(α1)₂β1δγ], and the switch from γ to ε occurs within the first few weeks of postnatal life in humans, producing a receptor with faster channel kinetics and shorter open time. This fetal-type γ-containing receptor is re-expressed throughout the muscle membrane (not just at the endplate) following denervation, upper motor neuron lesions, severe burns, prolonged immobilization, and crush injury — a process termed upregulation of extrajunctional receptors. These extrajunctional fetal-type receptors have prolonged open times and are the molecular basis for the life-threatening hyperkalemia that can follow succinylcholine administration in these populations.
2. Succinylcholine (suxamethonium) is the only clinically available depolarizing neuromuscular blocker and remains a mainstay of rapid sequence intubation (RSI) despite significant adverse effects. Its pharmacologic action at the NMJ proceeds through two mechanistically distinct phases — Phase I block and Phase II block — which are reliably distinguished at the bedside by their responses to train-of-four (TOF) stimulation and to acetylcholinesterase inhibitors. Which of the following statements most accurately characterizes Phase I versus Phase II succinylcholine block?
ANSWER: D
Rationale:
Phase I succinylcholine block is a classic depolarizing block. Succinylcholine binds the α1 subunits of the NMJ receptor, opens the channel, and produces sustained endplate depolarization that inactivates perijunctional voltage-gated sodium channels, rendering the muscle unresponsive to further nerve stimulation. Characteristic TOF features include proportionate reduction of all four twitches (T1 = T2 = T3 = T4, TOF ratio ≈ 1.0, no fade), absent post-tetanic facilitation, and potentiation — not antagonism — by anticholinesterases. Administering neostigmine during Phase I block worsens and prolongs paralysis by increasing synaptic acetylcholine, which adds to the depolarizing stimulus. Phase II block develops after large cumulative doses (typically >3–5 mg/kg, though the traditional teaching threshold is often cited as 7–10 mg/kg with repeated dosing or infusion) or after prolonged exposure, and its mechanism is poorly understood but involves receptor desensitization and ion channel effects that produce a block pharmacologically resembling nondepolarizing block. Phase II therefore exhibits TOF fade, post-tetanic facilitation, and variable but often partial reversibility with anticholinesterases. Neostigmine reversal of Phase II is unreliable and is generally not recommended clinically; spontaneous recovery is preferred.
3. Succinylcholine causes a transient rise in serum potassium of approximately 0.5 mEq/L in normal adults, which is generally clinically inconsequential. However, in several well-defined patient populations, succinylcholine can provoke life-threatening hyperkalemia with serum potassium rising to 8–12 mEq/L, triggering ventricular arrhythmias and cardiac arrest. Understanding the molecular mechanism of this exaggerated potassium release is critical for safe use. Which of the following most accurately explains the mechanism of exaggerated hyperkalemia in at-risk patients receiving succinylcholine?
ANSWER: E
Rationale:
The mechanism of exaggerated succinylcholine-induced hyperkalemia is upregulation of extrajunctional, fetal-type (γ-subunit-containing) and α7-containing nicotinic receptors across the entire sarcolemma, not just at the neuromuscular junction. Under normal conditions, mature (ε-containing) receptors are tightly clustered at the motor endplate, and succinylcholine depolarizes a small, spatially restricted membrane area, producing only a modest potassium efflux. When extrajunctional receptors proliferate, the depolarizing stimulus is applied to a much larger membrane surface, and the fetal-type and α7-containing channels have longer mean open times, resulting in massive potassium efflux. Serum potassium can rise by 5–10 mEq/L within minutes, with cardiac arrest typically occurring at levels above 8 mEq/L. Classic high-risk conditions include denervation injury (spinal cord injury, stroke, traumatic brain injury, Guillain-Barré syndrome, demyelinating disease), severe burns, prolonged immobilization or critical illness (>24–48 hours is the commonly cited threshold), crush injury and rhabdomyolysis, and certain myopathies (Duchenne muscular dystrophy, particularly in undiagnosed boys — a source of pediatric anesthesia-related cardiac arrest that led to the FDA black box warning). The risk window typically begins 24–72 hours after the inciting injury and can persist for months. Succinylcholine is also contraindicated in preexisting hyperkalemia and in malignant hyperthermia susceptibility.
4. The nondepolarizing neuromuscular blockers (NDNMBs) are divided into two major structural classes that differ in their elimination pathways, making one class or the other preferable in particular clinical settings such as hepatic or renal failure. Which of the following correctly pairs the structural class with its elimination characteristics and a representative agent?
ANSWER: A
Rationale:
Nondepolarizing neuromuscular blockers fall into two structural families. The aminosteroids — rocuronium, vecuronium, and pancuronium — are characterized by a steroid nucleus and are eliminated predominantly by hepatic metabolism and biliary excretion, with variable renal contribution. Pancuronium is the most renally dependent of the three (approximately 40–70% renal elimination), and its active metabolite 3-desacetylpancuronium accumulates in renal failure, prolonging blockade. Vecuronium is intermediate. Rocuronium is largely hepatobiliary with modest renal contribution (<30%). The benzylisoquinolines — atracurium, cisatracurium, and mivacurium — share the benzylisoquinolinium chemical scaffold. Atracurium and cisatracurium are unique in undergoing Hofmann elimination, a spontaneous, non-enzymatic degradation at physiologic pH and temperature that is independent of hepatic and renal function. This property makes cisatracurium particularly useful in patients with combined hepatic and renal failure, in the ICU setting, and in critically ill patients with multi-organ dysfunction. Cisatracurium is preferred over atracurium because it produces less laudanosine (a CNS-stimulant metabolite) and causes minimal histamine release. Mivacurium is the one benzylisoquinoline that is metabolized by plasma butyrylcholinesterase, making it short-acting but susceptible to prolongation in BChE-deficient patients.
5. Quantitative neuromuscular monitoring is mandatory for safe use of neuromuscular blocking agents, and the train-of-four (TOF) is the most commonly used bedside modality. A TOF ratio (T4/T1) less than 0.9 at the time of extubation is considered residual neuromuscular blockade and is associated with clinically significant adverse outcomes. Which of the following best describes the clinical significance of a TOF ratio less than 0.9 and its relationship to other monitoring modalities (double-burst stimulation [DBS] and post-tetanic count [PTC])?
ANSWER: B
Rationale:
A TOF ratio (the amplitude of T4 divided by T1) less than 0.9 defines residual neuromuscular blockade and has major clinical consequences. Pharyngeal and upper airway muscles are disproportionately sensitive to residual blockade compared with the adductor pollicis (the standard monitoring site), and clinical signs — including 5-second head lift, hand grip, and tidal volume — are insensitive and nonspecific, with patients retaining apparently normal strength despite TOF ratios of 0.4–0.7. Ratios below 0.9 are associated with impaired pharyngeal coordination, reduced upper esophageal sphincter tone, blunted hypoxic ventilatory response, increased aspiration risk, postoperative airway obstruction, hypoxemia, reintubation, and pulmonary complications including atelectasis and pneumonia. These findings underpin contemporary guidelines recommending quantitative (objective) monitoring — confirming TOF ratio ≥0.9 before extubation — rather than relying on qualitative (visual or tactile) assessment or clinical signs. Double-burst stimulation delivers two short tetanic bursts 750 ms apart; the fade between the two evoked responses is easier to detect by feel or eye than TOF fade, making DBS more sensitive than qualitative TOF for detecting residual block, though it still does not match the sensitivity of quantitative TOF. Post-tetanic count is used during deep neuromuscular block when there is no TOF response: a 5-second tetanic stimulus is followed by single twitches at 1 Hz, and the count of palpable twitches (PTC) provides an estimate of how deep the block is and when the first TOF twitch will reappear.
6. Reversal of nondepolarizing neuromuscular blockade is accomplished with either an acetylcholinesterase inhibitor (neostigmine, typically co-administered with glycopyrrolate) or the selective relaxant-binding agent sugammadex. The two approaches differ fundamentally in mechanism, spectrum of activity, and clinical performance. Which of the following statements most accurately compares neostigmine and sugammadex for reversal of rocuronium- or vecuronium-induced blockade?
ANSWER: C
Rationale:
Neostigmine is a carbamate acetylcholinesterase inhibitor that reverses nondepolarizing blockade indirectly by raising synaptic acetylcholine, which then competes with the NDNMB at the NMJ receptor. Because it relies on competition, neostigmine requires that enough receptors be already unbound for the mechanism to work — clinically, this means at least a TOF count of 2–4 (and ideally a visible TOF ratio of ≥0.4) before administration. Reversal from deep blockade (PTC zero, or TOF count <2) with neostigmine is slow, unreliable, and risks recurarization. Standard dose is 0.04–0.07 mg/kg, typically 2.5–5 mg in adults, with a ceiling effect beyond about 70 μg/kg — giving more does not hasten reversal and produces progressively greater muscarinic toxicity. Muscarinic side effects (bradycardia, bronchoconstriction, increased secretions, nausea, abdominal cramping) require co-administration of an antimuscarinic agent, typically glycopyrrolate (preferred over atropine because of its matched onset and absence of CNS penetration). Sugammadex is a modified γ-cyclodextrin — a ring-shaped sugar polymer with a hydrophobic cavity sized to accept the steroid nucleus of aminosteroidal NDNMBs. It binds rocuronium and vecuronium in a one-to-one stoichiometric complex with very high affinity, sequestering the NMB away from the NMJ receptor and producing rapid, complete reversal. Because its mechanism does not depend on receptor competition, sugammadex is effective from any depth of blockade, including profound (PTC = 0) blockade, with the appropriate dose (2 mg/kg for moderate reversal at TOF count ≥2; 4 mg/kg for deep reversal at PTC 1–2; 16 mg/kg for immediate reversal of a rocuronium RSI dose). Onset is 1.5–3 minutes. It is not effective for benzylisoquinoline NDNMBs (atracurium, cisatracurium, mivacurium) because their structure is incompatible with the cyclodextrin cavity. Notable adverse effects include bradycardia (rare, usually transient), hypersensitivity and rare anaphylaxis (approximately 1 in 2,500–20,000), and reduced efficacy of hormonal contraceptives for 7 days after administration (sugammadex binds progestins).
7. Nicotine produces complex, dose-dependent effects at autonomic ganglia that illustrate the biphasic nature of nicotinic receptor activation. At low concentrations, nicotine stimulates ganglionic transmission, but at higher concentrations or with prolonged exposure, it blocks transmission through receptor desensitization. This biphasic pattern is observed both in experimental settings and clinically, and understanding it is essential for interpreting nicotine's cardiovascular and autonomic effects in tobacco users. Which of the following most accurately describes the biphasic effects of nicotine at autonomic ganglia?
ANSWER: E
Rationale:
Nicotine's biphasic effects at autonomic ganglia represent a classic example of the concentration- and time-dependent actions of nicotinic receptor agonists. At low concentrations, nicotine binds to and activates the (α3)₂(β4)₃ nicotinic receptors that mediate fast synaptic transmission at both sympathetic and parasympathetic ganglia. This produces depolarization of postganglionic neurons, increased firing rate, and enhanced autonomic output. The initial stimulatory phase accounts for the acute cardiovascular effects seen with tobacco use, including increased heart rate, blood pressure, and catecholamine release. At higher concentrations or with sustained exposure, nicotine produces functional ganglionic blockade through two mechanisms: persistent depolarization that inactivates voltage-gated sodium channels (similar to the mechanism of succinylcholine at the NMJ) and receptor desensitization, where the nicotinic receptors become refractory to further activation despite continued agonist presence. This explains the tolerance observed in chronic tobacco users and the eventual diminishment of acute autonomic responses. The phenomenon also underlies the historical use of high-dose nicotine as a ganglionic blocking agent before the development of more selective antagonists. Option D focuses on presynaptic effects on acetylcholine release and depletion, which is not the primary mechanism of nicotine's ganglionic actions.
8. Hexamethonium and mecamylamine are prototypical ganglionic blocking agents that were among the first effective antihypertensive drugs, though they are now primarily of historical interest due to their severe side effects. Both agents block nicotinic transmission at autonomic ganglia but differ in their chemical properties and clinical characteristics. Which of the following best describes the mechanisms and clinical properties of hexamethonium and mecamylamine?
ANSWER: A
Rationale:
Hexamethonium was the first clinically effective ganglionic blocking agent and remains the prototypical example. It is a bis-quaternary ammonium compound (two quaternary nitrogen atoms connected by a hexyl chain) that acts as a competitive antagonist at ganglionic (α3)₂(β4)₃ nicotinic receptors. Because it is fully ionized at physiologic pH, hexamethonium does not cross the blood-brain barrier and its actions are confined to the periphery. Its clinical use was limited by severe orthostatic hypotension, paralytic ileus, urinary retention, dry mouth, and other consequences of complete autonomic blockade. Mecamylamine is a secondary amine (uncharged at physiologic pH) that not only blocks ganglionic nicotinic receptors competitively but also exhibits open-channel blocking properties — it can enter the nicotinic channel pore when open and physically occlude ion flow. Unlike hexamethonium, mecamylamine readily crosses the blood-brain barrier and can produce CNS effects including sedation, depression, psychiatric symptoms, and tremor. This CNS penetration, combined with its dual mechanism of action, made mecamylamine even more problematic clinically than hexamethonium, though its longer half-life offered some dosing convenience. Both drugs block transmission at all autonomic ganglia equally (sympathetic and parasympathetic) because both types express the same (α3)₂(β4)₃ receptor subtype. The development of more selective antihypertensive agents (diuretics, β-blockers, ACE inhibitors, calcium channel blockers) rendered ganglionic blockers obsolete for hypertension treatment by the 1970s, though mecamylamine has found limited modern use as a smoking cessation aid due to its ability to block CNS nicotinic receptors.
9. The (α4)₂(β2)₃ nicotinic receptor subtype is the predominant high-affinity nicotine-binding site in the mammalian brain and is the primary mediator of nicotine's rewarding and addictive properties. Varenicline (Chantix), a partial agonist at this receptor, leverages the unique pharmacological properties of partial agonism to aid smoking cessation. Which of the following best explains varenicline's mechanism of action and its advantages over other smoking cessation pharmacotherapies?
ANSWER: B
Rationale:
Varenicline is a partial agonist at the (α4)₂(β2)₃ nicotinic receptor subtype, which is the key mediator of nicotine addiction located primarily in dopaminergic neurons of the ventral tegmental area that project to the nucleus accumbens (the mesolimbic reward pathway). As a partial agonist, varenicline exhibits two complementary actions that make it uniquely effective for smoking cessation. First, varenicline provides modest intrinsic activity at (α4)₂(β2)₃ receptors (approximately 40–60% of nicotine's maximal effect), producing enough dopamine release in the nucleus accumbens to reduce withdrawal symptoms and craving without delivering the full rewarding effect that reinforces addiction. This allows patients to quit smoking with reduced discomfort. Second, when tobacco-derived nicotine is present, varenicline acts as a functional antagonist by occupying the receptors and preventing full nicotine activation. A partial agonist, by definition, cannot produce the same maximal response as a full agonist, regardless of concentration. This blunts the rewarding and reinforcing effects of smoking, reducing the patient's motivation to continue tobacco use and helping prevent relapse. This dual mechanism offers clear advantages over other pharmacotherapies. Nicotine replacement therapy (patch, gum, lozenge) provides only agonist activity and does not block the reinforcing effects of concurrent smoking. Bupropion works primarily through dopamine and norepinephrine reuptake inhibition and has no direct activity at nicotinic receptors, making it less specific for nicotine addiction mechanisms. Option D invokes GABA and glutamate mechanisms that are not varenicline's primary actions.
10. The (α7)₅ nicotinic receptor is a unique homomeric subtype with distinctive biophysical and pharmacological properties that distinguish it from heteromeric neuronal nicotinic receptors. This receptor subtype has gained considerable research attention due to its involvement in cognitive processes and its potential role in psychiatric disorders, particularly schizophrenia. Which of the following best describes the (α7)₅ nicotinic receptor and its clinical significance?
ANSWER: B
Rationale:
The (α7)₅ nicotinic receptor is a homomeric pentamer composed entirely of α7 subunits, giving it unique biophysical properties that distinguish it from all heteromeric nicotinic receptors. Most notably, it exhibits extraordinarily high calcium permeability, with a calcium-to-sodium permeability ratio (P_Ca/P_Na) of approximately 10, making it one of the most calcium-permeable ligand-gated ion channels in the nervous system. This high calcium flux can trigger calcium-dependent signaling cascades, including activation of calcium/calmodulin-dependent protein kinase II (CaMKII) and cAMP response element-binding protein (CREB), linking (α7)₅ activation to synaptic plasticity and gene transcription. The (α7)₅ receptor also exhibits extremely rapid desensitization kinetics, entering a desensitized state within milliseconds of activation and recovering slowly. This property means that sustained agonist exposure produces primarily desensitized receptors, limiting the duration of channel opening but potentially allowing the desensitized receptor to serve signaling functions independent of ion flux. The (α7)₅ receptor is highly expressed in hippocampus, prefrontal cortex, and other brain regions critical for cognitive function. There is substantial evidence that (α7)₅ dysfunction contributes to the cognitive deficits and sensory gating abnormalities observed in schizophrenia. Patients with schizophrenia show reduced (α7)₅ receptor expression, impaired auditory sensory gating (measured by P50 suppression), and deficits in working memory and attention — all functions linked to (α7)₅ activity. The high prevalence of smoking in schizophrenia (80–90% vs 20% in the general population) may represent an attempt at self-medication to compensate for (α7)₅ hypofunction. These findings have generated considerable interest in developing (α7)₅-selective positive allosteric modulators and partial agonists as cognitive enhancers for schizophrenia and other disorders characterized by cognitive dysfunction, including Alzheimer's disease and attention deficit disorders.
11. Beyond its actions at nicotinic receptors, nicotine produces significant systemic pharmacological effects that account for many of the acute physiological responses to tobacco use and the cardiovascular risks associated with smoking. Understanding nicotine's systemic pharmacology is essential for clinicians managing patients who smoke or use nicotine replacement therapy. Which of the following best describes nicotine's systemic pharmacological effects and their clinical significance?
ANSWER: D
Rationale:
Nicotine produces its systemic cardiovascular effects through multiple, synergistic mechanisms that collectively increase cardiovascular risk. The primary pathways include: (1) Ganglionic stimulation: activation of (α3)₂(β4)₃ receptors at sympathetic ganglia increases sympathetic nervous system outflow, leading to increased heart rate, myocardial contractility, and peripheral vasoconstriction. (2) Adrenal medullary stimulation: nicotine directly activates chromaffin cells in the adrenal medulla (which are essentially modified sympathetic postganglionic neurons), causing release of epinephrine and norepinephrine into the systemic circulation. (3) Central nervous system effects: nicotine crosses the blood-brain barrier and can influence cardiovascular control centers in the brainstem, contributing to sympathetic activation. The net result is significant increases in heart rate (typically 10–20 bpm), systolic and diastolic blood pressure (10–20 mmHg), myocardial contractility, and coronary vascular resistance. These changes increase myocardial oxygen demand substantially. Simultaneously, nicotine can reduce coronary blood flow through direct coronary vasoconstriction and by promoting platelet aggregation and thrombosis, potentially reducing oxygen supply to the myocardium. This mismatch between increased oxygen demand and potentially reduced supply is particularly dangerous in patients with underlying coronary artery disease, and acute myocardial infarction has been documented following nicotine exposure in vulnerable patients. The cardiovascular effects are dose-dependent and can be observed with nicotine replacement therapy, though the risks are generally considered acceptable when weighed against continued smoking. Chronic nicotine exposure also contributes to endothelial dysfunction, accelerated atherosclerosis, and increased thrombotic risk through effects on nitric oxide synthesis, inflammatory mediators, and coagulation factors. Option E is dangerously incorrect about cardiovascular benefits.
12. Lambert-Eaton myasthenic syndrome (LEMS) and myasthenia gravis (MG) are both disorders of neuromuscular transmission but differ fundamentally in their pathophysiology, clinical presentation, and response to pharmacological interventions. Understanding these differences is crucial for appropriate diagnosis and management. Which of the following best characterizes the key differences between LEMS and MG?
ANSWER: E
Rationale:
LEMS and MG represent presynaptic versus postsynaptic disorders of neuromuscular transmission, respectively, with fundamentally different pathophysiology leading to opposite exercise responses. In LEMS, autoantibodies target voltage-gated calcium channels (VGCCs), particularly the P/Q-type (Cav2.1) subtype, located in the presynaptic terminal of motor neurons. These calcium channels are essential for triggering acetylcholine release through calcium-induced exocytosis. When antibodies reduce functional calcium channel number or activity, less calcium enters the terminal per action potential, resulting in reduced acetylcholine release and impaired neuromuscular transmission. The characteristic improvement with exercise in LEMS occurs because repetitive nerve stimulation gradually increases intracellular calcium through several mechanisms: calcium accumulation from repeated influx, facilitation of remaining calcium channels, and recruitment of additional release sites. This explains the classic incremental response seen on repetitive nerve stimulation studies (>100% increase in compound muscle action potential amplitude) and the clinical phenomenon of patients becoming stronger as they continue exercising. MG involves antibodies directed against the postsynaptic nicotinic acetylcholine receptors (most commonly the α1 subunit). These antibodies either block acetylcholine binding competitively or trigger complement-mediated receptor destruction and internalization, reducing the number of functional postsynaptic receptors. With fewer receptors available, the safety factor for neuromuscular transmission is reduced. In MG, exercise worsens weakness because repeated stimulation progressively depletes the readily releasable pool of acetylcholine vesicles faster than they can be replenished. With reduced postsynaptic receptor numbers, this declining acetylcholine release eventually falls below the threshold needed to trigger muscle contraction, leading to fatigue and weakness. This explains the decremental response on repetitive stimulation studies and the clinical pattern of weakness that worsens throughout the day or with sustained activity. LEMS is frequently associated with small-cell lung cancer (paraneoplastic syndrome), while MG often associates with thymic abnormalities. Acetylcholinesterase inhibitors (pyridostigmine) are highly effective in MG but show limited benefit in LEMS because the problem is insufficient acetylcholine release rather than receptor blockade.